desferrioxamine therapy
Recently Published Documents


TOTAL DOCUMENTS

25
(FIVE YEARS 0)

H-INDEX

10
(FIVE YEARS 0)

2008 ◽  
Vol 89 (4) ◽  
pp. 868-873 ◽  
Author(s):  
C. Giardini ◽  
M. Galimbbrti ◽  
G. Lucarelli ◽  
P. Polchi ◽  
E. Angelucci ◽  
...  

2007 ◽  
Vol 122 (11) ◽  
pp. 1253-1256 ◽  
Author(s):  
D Thio ◽  
V Prasad ◽  
P Anslow ◽  
P Lennox

AbstractObjective:The aim of this report was to highlight the fact that hearing loss in thalassaemia patients can be related to marrow expansion affecting the ossicles, resulting in a conductive loss.Case report:A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy. Otoxicity was assumed, but the deficit was later found to be of a conductive nature, due to marrow proliferation within the ossicular chain as a consequence of the disease process – a phenomenon previously unreported in the literature.Conclusion:It is important to elucidate the precise nature of new onset hearing loss in patients receiving iron chelation therapy, in order to avoid unnecessary cessation of much needed medication, on the assumption of ototoxicity.


2005 ◽  
Vol 5 (7) ◽  
pp. 572-578 ◽  
Author(s):  
Vasili Berdoukas ◽  
Timothy Bohane ◽  
Vivienne Tobias ◽  
Keshani De Silva ◽  
Ian Fraser ◽  
...  

1998 ◽  
Vol 18 (5) ◽  
pp. 420-424 ◽  
Author(s):  
Dimitrios I. Zafeiriou ◽  
Afroditi A. Kousi ◽  
Chaido T. Tsantali ◽  
Eleftherios E. Kontopoulos ◽  
Persa A. Augoustidou-Savvopoulou ◽  
...  

1996 ◽  
Vol 16 (2) ◽  
pp. 45-48 ◽  
Author(s):  
C. Salvarani ◽  
R. Baricchi ◽  
D. Lasagni ◽  
L. Boiardi ◽  
R. Piccinini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document